Authors: Gulbrandsen, N Wisloff, F Brinch, L Carlson, K Dahl, IM Gimsing, P Hippe, E Hjorth, M Knudsen, LM Lamvik, J Lenhoff, S Lofvenberg, E Nesthus, I Nielsen, JL Turesson, L Westin, J

Citation: N. Gulbrandsen et al., Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support, MED ONCOL, 18(1), 2001, pp. 65-77

Authors: Gulbrandsen, N Wisloff, F Nord, E Lenhoff, S Hjorth, M Westin, J

Citation: N. Gulbrandsen et al., Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma, EUR J HAEMA, 66(5), 2001, pp. 328-336

Authors: Wisloff, F Gulbrandsen, N

Citation: F. Wisloff et N. Gulbrandsen, Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients, ACTA ONCOL, 39(7), 2000, pp. 809-813

Authors: Wisloff, F Gulbrandsen, N Nord, E

Citation: F. Wisloff et al., Therapeutic options in the treatment of multiple myeloma - Pharmacoeconomic and quality-of-life considerations, PHARMACOECO, 16(4), 1999, pp. 329-341